Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Cousens

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical & Developmental Immunology|January 24, 2014
Tregitope peptides: the active pharmaceutical ingredient of IVIG?Anne S De Groot, Leslie Cousens, Federico Mingozzi, et al.
Expert Review of Clinical Pharmacology|October 30, 2013
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologicsAnne S De Groot, Frances Terry, Leslie Cousens, et al.
Expert Opinion on Drug Discovery|June 1, 2012
Harnessing the power of genomics and immunoinformatics to produce improved vaccinesLeonard Moise, Leslie Cousens, Joanna Fueyo, et al.
Human Immunology|December 3, 2014
Tregitope: Immunomodulation powerhouseLeslie Cousens, Nader Najafian, William D Martin, et al.
Rhode Island Medical Journal (2013)|May 4, 2013
Building better biotherapeutics and vaccines by design: EpiVax, Inc., an immunology companyLeonard Moise, Annie De Groot, Anthony Marcello, et al.
Journal of Hepatology|May 24, 2003
Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas receptorMarcus Wiedmann, Seishu Tamaki, Rebecca Silberman, et al.
BMJ Open|December 22, 2022
Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysisSpoorthy Kulkarni, Hannah Durham, Luke Glover, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 7, 2022
Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: A randomized controlled clinical trialCaroline P E Price, Amina Guo, Whitney W Stevens, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical & Developmental Immunology|January 24, 2014
Tregitope peptides: the active pharmaceutical ingredient of IVIG?Anne S De Groot, Leslie Cousens, Federico Mingozzi, et al.
Expert Review of Clinical Pharmacology|October 30, 2013
Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologicsAnne S De Groot, Frances Terry, Leslie Cousens, et al.
Expert Opinion on Drug Discovery|June 1, 2012
Harnessing the power of genomics and immunoinformatics to produce improved vaccinesLeonard Moise, Leslie Cousens, Joanna Fueyo, et al.
Human Immunology|December 3, 2014
Tregitope: Immunomodulation powerhouseLeslie Cousens, Nader Najafian, William D Martin, et al.
Rhode Island Medical Journal (2013)|May 4, 2013
Building better biotherapeutics and vaccines by design: EpiVax, Inc., an immunology companyLeonard Moise, Annie De Groot, Anthony Marcello, et al.
Journal of Hepatology|May 24, 2003
Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas receptorMarcus Wiedmann, Seishu Tamaki, Rebecca Silberman, et al.
BMJ Open|December 22, 2022
Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysisSpoorthy Kulkarni, Hannah Durham, Luke Glover, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 7, 2022
Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: A randomized controlled clinical trialCaroline P E Price, Amina Guo, Whitney W Stevens, et al.
Pageof 1